{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T09:54:39Z","timestamp":1794045279440,"version":"4.8.0"},"reference-count":58,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Continuum"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1212\/con.0000000000000309","type":"journal-article","created":{"date-parts":[[2016,4,19]],"date-time":"2016-04-19T13:15:42Z","timestamp":1461071742000},"page":"435-463","source":"Crossref","is-referenced-by-count":186,"title":["Lewy Body Dementias"],"prefix":"10.1212","volume":"22","author":[{"given":"Stephen N.","family":"Gomperts","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_1_2_2","unstructured":"Lewy FH. Paralysis agitans. I. Pathologische Anatomie. Lewandowsky\u2019s Handbuch der Neurologie 3 Band: Spez Neurologie II. Berlin Germany: Springer 1912: 920\u2013933."},{"key":"e_1_3_1_5_2","doi-asserted-by":"crossref","unstructured":"Lippa CF Duda JE Grossman M et al.; DLB\/PDD Working Group. DLB and PDD boundary issues: diagnosis treatment molecular pathology and biomarkers. Neurology 2007; 68(11): 812\u2013819. doi:10.1212\/01.wnl.0000256715.13907.d3.","DOI":"10.1212\/01.wnl.0000256715.13907.d3"},{"key":"e_1_3_1_6_2","doi-asserted-by":"crossref","unstructured":"McKeith IG Dickson DW Lowe J et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005; 65(12): 1863\u20131872. doi:10.1212\/01.wnl.0000187889.17253.b1.","DOI":"10.1212\/wnl.65.12.1992-a"},{"key":"e_1_3_1_7_2","doi-asserted-by":"crossref","unstructured":"Emre M Aarsland D Brown R et al. Clinical diagnostic criteria for dementia associated with Parkinson\u2019s disease. Mov Disord 2007; 22(12): 1689\u20131707. doi:10.1002\/mds.21507.","DOI":"10.1002\/mds.21507"},{"key":"e_1_3_1_8_2","doi-asserted-by":"crossref","unstructured":"Harding AJ Halliday GM. Cortical Lewy body pathology in the diagnosis of dementia. Acta Neuropathol 2001; 102(4): 355\u2013363. doi:10.1007\/s004010100390.","DOI":"10.1007\/s004010100390"},{"key":"e_1_3_1_9_2","doi-asserted-by":"crossref","unstructured":"Fearnley JM Lees AJ. Ageing and Parkinson\u2019s disease: substantia nigra regional selectivity. Brain 1991; 114(pt 5): 2283\u20132301. doi:10.1093\/brain\/114.5.2283 2283\u20132301.","DOI":"10.1093\/brain\/114.5.2283"},{"key":"e_1_3_1_10_2","doi-asserted-by":"crossref","unstructured":"Tiraboschi P Hansen LA Alford M et al. Cholinergic dysfunction in diseases with Lewy bodies. Neurology 2000; 54(2): 407\u2013411. doi:10.1212\/WNL.54.2.407.","DOI":"10.1212\/WNL.54.2.407"},{"key":"e_1_3_1_11_2","doi-asserted-by":"crossref","unstructured":"Mattila PM R\u00f6ytt\u00e4 M Torikka H et al. Cortical Lewy bodies and Alzheimer-type changes in patients with Parkinson\u2019s disease. Acta Neuropathol 1998; 95(6): 576\u2013582. doi:10.1007\/s004010050843.","DOI":"10.1007\/s004010050843"},{"key":"e_1_3_1_12_2","doi-asserted-by":"crossref","unstructured":"McKeith IG Burn D. Spectrum of Parkinson\u2019s disease Parkinson\u2019s dementia and Lewy body dementia. In: DeKosky ST ed. Neurologic clinics. Philadelphia PA: WB Saunders 2000: 865\u2013883.","DOI":"10.1016\/S0733-8619(05)70230-9"},{"key":"e_1_3_1_13_2","doi-asserted-by":"crossref","unstructured":"Aarsland D Ballard CG Halliday G. Are Parkinson\u2019s disease with dementia and dementia with Lewy bodies the same entity? J Geriatr Psychiatry Neurol 2004; 17(3): 137\u2013145. doi:10.1177\/0891988704267470.","DOI":"10.1177\/0891988704267470"},{"key":"e_1_3_1_14_2","doi-asserted-by":"crossref","unstructured":"Lee DR McKeith I Mosimann U et al. The dementia cognitive fluctuation scale a new psychometric test for clinicians to identify cognitive fluctuations in people with dementia. Am J Geriatr Psychiatry 2014; 22(9): 926\u2013935. doi:10.1016\/j.jagp.2013.01.072.","DOI":"10.1016\/j.jagp.2013.01.072"},{"key":"e_1_3_1_15_2","doi-asserted-by":"crossref","unstructured":"Donaghy PC O\u2019Brien JT Thomas AJ. Prodromal dementia with Lewy bodies. Psychol Med 2015: 45(2): 259\u2013268. doi:10.1017\/S0033291714000816.","DOI":"10.1017\/S0033291714000816"},{"key":"e_1_3_1_16_2","doi-asserted-by":"crossref","unstructured":"Yoshita M Arai H Arai H et al. Diagnostic accuracy of 123I-meta-iodobenzylguanidine myocardial scintigraphy in dementia with Lewy bodies: a multicenter study. PLoS One 2015; 10(3): e0120540. doi:10.1371\/journal.pone.0120540.","DOI":"10.1371\/journal.pone.0120540"},{"key":"e_1_3_1_17_2","doi-asserted-by":"crossref","unstructured":"Huang Y Halliday G. Can we clinically diagnose dementia with Lewy bodies yet? Transl Neurodegener 2013; 2(1): 4. doi:10.1186\/2047-9158-2-4.","DOI":"10.1186\/2047-9158-2-4"},{"key":"e_1_3_1_18_2","doi-asserted-by":"crossref","unstructured":"Finger EC. Frontotemporal dementias. Continuum (Minneap Minn) 2016; 22(2 Dementia): 464\u2013489.","DOI":"10.1212\/CON.0000000000000300"},{"key":"e_1_3_1_19_2","unstructured":"Parkinson J. An essay on the shaking palsy. England: Sherwood Neely and Jones 1817."},{"key":"e_1_3_1_21_2","doi-asserted-by":"crossref","unstructured":"Locascio JJ Corkin S Growdon JH. Relation between clinical characteristics of Parkinson\u2019s disease and cognitive decline. J Clin Exp Neuropsychol 2003; 25(1): 94\u2013109. doi:10.1076\/jcen.25.1.94.13624.","DOI":"10.1076\/jcen.25.1.94.13624"},{"key":"e_1_3_1_22_2","doi-asserted-by":"crossref","unstructured":"Mortimer JA Pirozzolo FJ Hansch EC Webster DD. Relationship of motor symptoms to intellectual deficits in Parkinson disease. Neurology 1982; 32(2): 133\u2013137. doi:10.1212\/WNL.32.2.133.","DOI":"10.1212\/WNL.32.2.133"},{"key":"e_1_3_1_23_2","doi-asserted-by":"crossref","unstructured":"Hughes AJ Daniel SE Blankson S Lees AJ. A clinicopathologic study of 100 cases of Parkinson\u2019s disease. Arch Neurol 1993; 50(2): 140\u2013148. doi:10.1001\/archneur.1993.00540020018011.","DOI":"10.1001\/archneur.1993.00540020018011"},{"key":"e_1_3_1_24_2","doi-asserted-by":"crossref","unstructured":"Litvan I Goldman JG Tr\u00f6ster AI et al. Diagnostic criteria for mild cognitive impairment in Parkinson\u2019s disease: Movement Disorder Society Task Force guidelines. Mov Disord 2012; 27(3): 349\u2013356. doi:10.1002\/mds.24893.","DOI":"10.1002\/mds.24893"},{"key":"e_1_3_1_25_2","doi-asserted-by":"crossref","unstructured":"Aarsland D Andersen K Larsen JP et al. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 2003; 60(3): 387\u2013392. doi:10.1001\/archneur.60.3.387.","DOI":"10.1001\/archneur.60.3.387"},{"key":"e_1_3_1_26_2","doi-asserted-by":"crossref","unstructured":"Hughes TA Ross HF Musa S et al. A 10-year study of the incidence of and factors predicting dementia in Parkinson\u2019s disease. Neurology 2000; 54(8): 1596\u20131602. doi:10.1212\/WNL.54.8.1596.","DOI":"10.1212\/WNL.54.8.1596"},{"key":"e_1_3_1_27_2","doi-asserted-by":"crossref","unstructured":"Mayeux R Chen J Mirabello E et al. An estimate of the incidence of dementia in idiopathic Parkinson\u2019s disease. Neurology 1990; 40(10): 1513\u20131517. doi:10.1212\/WNL.40.10.1513.","DOI":"10.1212\/WNL.40.10.1513"},{"key":"e_1_3_1_28_2","doi-asserted-by":"crossref","unstructured":"Uc EY McDermott MP Marder KS et al.; Parkinson Study Group DATATOP Investigators. Incidence of and risk factors for cognitive impairment in an early Parkinson disease clinical trial cohort. Neurology 2009; 73(18): 1469\u20131477. doi:10.1212\/WNL.0b013e3181bf992f.","DOI":"10.1212\/WNL.0b013e3181bf992f"},{"key":"e_1_3_1_29_2","doi-asserted-by":"crossref","unstructured":"Kempster PA O\u2019Sullivan SS Holton JL et al. Relationships between age and late progression of Parkinson\u2019s disease: a clinico-pathological study. Brain 2010; 133(pt 6): 1755\u20131762. doi:10.1093\/brain\/awq059.","DOI":"10.1093\/brain\/awq059"},{"key":"e_1_3_1_30_2","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders fifth edition. Washington DC: American Psychiatric Publishing 2013.","DOI":"10.1176\/appi.books.9780890425596"},{"key":"e_1_3_1_31_2","doi-asserted-by":"crossref","unstructured":"Berg D Postuma RB Bloem B et al. Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson\u2019s disease. Mov Disord 2014; 29(4): 454\u2013462. doi:10.1002\/mds.25844.","DOI":"10.1002\/mds.25844"},{"key":"e_1_3_1_32_2","doi-asserted-by":"crossref","unstructured":"Mak E Su L Williams GB O\u2019Brien JT. Neuroimaging characteristics of dementia with Lewy bodies. Alzheimers Res Ther 2014; 6(2): 18. doi:10.1186\/alzrt248.","DOI":"10.1186\/alzrt248"},{"key":"e_1_3_1_33_2","doi-asserted-by":"crossref","unstructured":"Davison CM O\u2019Brien JT. A comparison of FDG-PET and blood flow SPECT in the diagnosis of neurodegenerative dementias: a systematic review. Int J Geriatr Psychiatry 2014; 29(6): 551\u2013561. doi:10.1002\/gps.4036.","DOI":"10.1002\/gps.4036"},{"key":"e_1_3_1_34_2","doi-asserted-by":"crossref","unstructured":"Jokinen P Scheinin N Aalto S et al. [(11)C]PIB- [(18)F]FDG-PET and MRI imaging in patients with Parkinson\u2019s disease with and without dementia. Parkinsonism Relat Disord 2010; 16(10): 666\u2013670. doi:10.1016\/j.parkreldis.2010.08.021.","DOI":"10.1016\/j.parkreldis.2010.08.021"},{"key":"e_1_3_1_35_2","doi-asserted-by":"crossref","unstructured":"Bohnen NI Koeppe RA Minoshima S et al. Cerebral glucose metabolic features of Parkinson disease and incident dementia: longitudinal study. J Nucl Med 2011; 52(6): 848\u2013855. doi:10.2967\/jnumed.111.089946.","DOI":"10.2967\/jnumed.111.089946"},{"key":"e_1_3_1_36_2","doi-asserted-by":"crossref","unstructured":"Singh TD Josephs KA Machulda MM et al. Clinical FDG and amyloid PET imaging in posterior cortical atrophy. J Neurol 2015; 262(6): 1483\u20131492. doi:10.1007\/s00415-015-7732-5.","DOI":"10.1007\/s00415-015-7732-5"},{"key":"e_1_3_1_37_2","doi-asserted-by":"crossref","unstructured":"Lle\u00f3 A Cavedo E Parnetti L et al. Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases. Nat Rev Neurol 2015; 11(1): 41\u201355. doi:10.1038\/nrneurol.2014.232.","DOI":"10.1038\/nrneurol.2014.232"},{"key":"e_1_3_1_38_2","doi-asserted-by":"crossref","unstructured":"Kawai Y Suenaga M Takeda A et al. Cognitive impairments in multiple system atrophy: MSA-C vs MSA-P. Neurology 2008; 70(16 pt 2): 1390\u20131396. doi:10.1212\/01.wnl.0000310413.04462.6a.","DOI":"10.1212\/01.wnl.0000310413.04462.6a"},{"key":"e_1_3_1_39_2","doi-asserted-by":"crossref","unstructured":"Kitayama M Wada-Isoe K Irizawa Y Nakashima K. Assessment of dementia in patients with multiple system atrophy. Eur J Neurol 2009; 16(5): 589\u2013594. doi:10.1111\/j.1468\u20131331.2009.02544.x.","DOI":"10.1111\/j.1468-1331.2009.02544.x"},{"key":"e_1_3_1_40_2","doi-asserted-by":"crossref","unstructured":"Gilman S Wenning GK Low PA et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 2008; 71(9): 670\u2013676. doi:10.1212\/01.wnl.0000324625.00404.15.","DOI":"10.1212\/01.wnl.0000324625.00404.15"},{"key":"e_1_3_1_41_2","doi-asserted-by":"crossref","unstructured":"Ib\u00e1\u00f1ez P Lesage S Janin S et al.; French Parkinson\u2019s Disease Genetics Study Group. Alpha-synuclein gene rearrangements in dominantly inherited parkinsonism: frequency phenotype and mechanisms. Arch Neurol 2009; 66(1): 102\u2013108. doi:10.1001\/archneurol.2008.555.","DOI":"10.1001\/archneurol.2008.555"},{"key":"e_1_3_1_42_2","doi-asserted-by":"crossref","unstructured":"Sidransky E Nalls MA Aasly JO et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson\u2019s disease. N Engl J Med 2009; 361(17): 1651\u20131661. doi:10.1056\/NEJMoa0901281.","DOI":"10.1056\/NEJMoa0901281"},{"key":"e_1_3_1_43_2","doi-asserted-by":"crossref","unstructured":"Schapira AH. Glucocerebrosidase and Parkinson disease: recent advances. Mol Cell Neurosci 2015; 66(pt A): 37\u201342. doi:10.1016\/j.mcn.2015.03.013.","DOI":"10.1016\/j.mcn.2015.03.013"},{"key":"e_1_3_1_44_2","doi-asserted-by":"crossref","unstructured":"Srivatsal S Cholerton B Leverenz JB et al. Cognitive profile of LRRK2-related Parkinson\u2019s disease. Mov Disord 2015; 30(5): 728\u2013733. doi:10.1002\/mds.26161.","DOI":"10.1002\/mds.26161"},{"key":"e_1_3_1_45_2","doi-asserted-by":"crossref","unstructured":"Tsuang D Leverenz JB Lopez OL et al. APOE \u03b54 increases risk for dementia in pure synucleinopathies. JAMA Neurol 2013; 70(2): 223\u2013228. doi:10.1001\/jamaneurol.2013.600.","DOI":"10.1001\/jamaneurol.2013.600"},{"key":"e_1_3_1_46_2","doi-asserted-by":"crossref","unstructured":"Mollenhauer B Rochester L Chen-Plotkin A Brooks D. What can biomarkers tell us about cognition in Parkinson\u2019s disease? Mov Disord 2014; 29(5): 622\u2013633. doi:10.1002\/mds.25846.","DOI":"10.1002\/mds.25846"},{"key":"e_1_3_1_47_2","doi-asserted-by":"crossref","unstructured":"Galasko DR. Dementia with Lewy bodies. Continuum (Minneap Minn) 2007; 13(2 Dementia): 69\u201386. doi:10.1212\/01.CON.0000267236.07498.38.","DOI":"10.1212\/01.CON.0000267236.07498.38"},{"key":"e_1_3_1_48_2","doi-asserted-by":"crossref","unstructured":"Wang HF Yu JT Tang SW et al. Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson\u2019s disease Parkinson\u2019s disease dementia and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis. J Neurol Neurosurg Psychiatry 2015; 86(2): 135\u2013143. doi:10.1136\/jnnp-2014-307659.","DOI":"10.1136\/jnnp-2014-307659"},{"key":"e_1_3_1_49_2","doi-asserted-by":"crossref","unstructured":"Cummings JL Geldmacher D Farlow M et al. High-dose donepezil (23 mg\/day) for the treatment of moderate and severe Alzheimer\u2019s disease: drug profile and clinical guidelines. CNS Neurosci Ther 2013; 19(5): 294\u2013301. doi:10.1111\/cns.12076.","DOI":"10.1111\/cns.12076"},{"key":"e_1_3_1_50_2","doi-asserted-by":"crossref","unstructured":"Connolly BS Lang AE. Pharmacological treatment of Parkinson disease: a review. JAMA 2014; 311(16): 1670\u20131683. doi:10.1001\/jama.2014.3654.","DOI":"10.1001\/jama.2014.3654"},{"key":"e_1_3_1_51_2","doi-asserted-by":"crossref","unstructured":"Gareri P De Fazio P Manfredi VG De Sarro G. Use and safety of antipsychotics in behavioral disorders in elderly people with dementia. J Clin Psychopharmacol 2014; 34(1): 109\u2013123. doi:10.1097\/JCP.0b013e3182a6096e.","DOI":"10.1097\/JCP.0b013e3182a6096e"},{"key":"e_1_3_1_52_2","doi-asserted-by":"crossref","unstructured":"Braak H Del Tredici K R\u00fcb U et al. Staging of brain pathology related to sporadic Parkinson\u2019s disease. Neurobiol Aging 2003; 24(2): 197\u2013211. doi:10.1016\/S0197-4580(02)00065-9.","DOI":"10.1016\/S0197-4580(02)00065-9"},{"key":"e_1_3_1_53_2","doi-asserted-by":"crossref","unstructured":"Kramer ML Schulz-Schaeffer WJ. Presynaptic alpha-synuclein aggregates not Lewy bodies cause neurodegeneration in dementia with Lewy bodies. J Neurosci 2007; 27(6): 1405\u20131410. doi:10.1523\/JNEUROSCI.4564-06.2007.","DOI":"10.1523\/JNEUROSCI.4564-06.2007"},{"key":"e_1_3_1_54_2","doi-asserted-by":"crossref","unstructured":"Nemani VM Lu W Berge V et al. Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron 2010; 65(1): 66\u201379. doi:10.1016\/j.neuron.2009.12.023.","DOI":"10.1016\/j.neuron.2009.12.023"},{"key":"e_1_3_1_55_2","doi-asserted-by":"crossref","unstructured":"Gomperts SN. Imaging the role of amyloid in PD dementia and dementia with Lewy bodies. Curr Neurol Neurosci Rep 2014; 14(8): 472. doi:10.1007\/s11910-014-0472-6.","DOI":"10.1007\/s11910-014-0472-6"},{"key":"e_1_3_1_56_2","doi-asserted-by":"crossref","unstructured":"Brooks DJ Piccini P. Imaging in Parkinson\u2019s disease: the role of monoamines in behavior. Biol Psychiatry 2006; 59(10): 908\u2013918. doi:10.1016\/j.biopsych.2005.12.017.","DOI":"10.1016\/j.biopsych.2005.12.017"},{"key":"e_1_3_1_57_2","doi-asserted-by":"crossref","unstructured":"Marquie M Locascio JJ Rentz DM et al. Striatal and extrastriatal dopamine transporter levels relate to cognition in Lewy body diseases: an (11)C altropane positron emission tomography study. Alzheimers Res Ther 2014; 6(5\u20138): 52. doi:10.1186\/s13195-014-0052-7.","DOI":"10.1186\/s13195-014-0052-7"},{"key":"e_1_3_1_58_2","doi-asserted-by":"crossref","unstructured":"Petrou M Kotagal V Bohnen NI. An update on brain imaging in parkinsonian dementia. Imaging Med 2012; 4(2): 201\u2013213. doi:10.2217\/iim.12.10.","DOI":"10.2217\/iim.12.10"},{"key":"e_1_3_1_59_2","doi-asserted-by":"crossref","unstructured":"Delli Pizzi S Franciotti R Tartaro A et al. Structural alteration of the dorsal visual network in DLB patients with visual hallucinations: a cortical thickness MRI study. PLoS One 2014; 9(1): e86624. doi:10.1371\/journal.pone.0086624.","DOI":"10.1371\/journal.pone.0086624"},{"key":"e_1_3_1_60_2","doi-asserted-by":"crossref","unstructured":"Boeve BF. Idiopathic REM sleep behaviour disorder in the development of Parkinson\u2019s disease. Lancet Neurol 2013; 12(5): 469\u2013482. doi:10.1016\/S1474-4422(13)70054-1.","DOI":"10.1016\/S1474-4422(13)70054-1"},{"key":"e_1_3_1_61_2","doi-asserted-by":"crossref","unstructured":"Gelpi E Navarro-Otano J Tolosa E et al. Multiple organ involvement by alpha-synuclein pathology in Lewy body disorders. Mov Disord 2014; 29(8): 1010\u20131018. doi:10.1002\/mds.25776.","DOI":"10.1002\/mds.25776"},{"key":"e_1_3_1_62_2","doi-asserted-by":"crossref","unstructured":"Panza F Solfrizzi V Imbimbo BP Logroscino G. Amyloid-directed monoclonal antibodies for the treatment of Alzheimer\u2019s disease: the point of no return? Expert Opin Biol Ther 2014; 14(10): 1465\u20131476. doi:10.1517\/14712598.2014.935332.","DOI":"10.1517\/14712598.2014.935332"}],"container-title":["Continuum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1212\/CON.0000000000000309","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T14:01:15Z","timestamp":1752156075000},"score":1,"resource":{"primary":{"URL":"https:\/\/continuum.aan.com\/doi\/10.1212\/CON.0000000000000309"}},"subtitle":["Dementia With Lewy Bodies and Parkinson Disease Dementia"],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":58,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["10.1212\/CON.0000000000000309"],"URL":"https:\/\/doi.org\/10.1212\/con.0000000000000309","relation":{},"ISSN":["1080-2371","1538-6899"],"issn-type":[{"value":"1080-2371","type":"print"},{"value":"1538-6899","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4]]}}}